BIOMARIN PHAR. DL-,001BIOMARIN PHAR. DL-,001BIOMARIN PHAR. DL-,001

BIOMARIN PHAR. DL-,001

No trades
See on Supercharts
Market capitalization
‪16.24 B‬EUR
‪151.89 M‬EUR
‪2.19 B‬EUR
‪185.93 M‬
Beta (1Y)
0.32

About BIOMARIN PHAR. DL-,001

CEO
Alexander Hardy
Headquarters
San Rafael
Employees (FY)
‪3.4 K‬
Founded
1997
ISIN
US09061G1013
FIGI
BBG000DB0R28
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where BM8 is featured.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange BIOMARIN PHAR. DL-,001 stocks are traded under the ticker BM8.
BIOMARIN PHAR. DL-,001 is going to release the next earnings report on Apr 24, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for BIOMARIN PHAR. DL-,001 has a max estimate of 131.60 EUR and a min estimate of 75.20 EUR.
BM8 earnings for the last quarter are 0.20 EUR whereas the estimation was 0.21 EUR which accounts for −5.20% surprise. Estimated earnings for the next quarter are 0.18 EUR. See more details about BIOMARIN PHAR. DL-,001 earnings.
BIOMARIN PHAR. DL-,001 revenue for the last quarter amounts to ‪549.93 M‬ EUR despite the estimated figure of ‪571.23 M‬ EUR. In the next quarter revenue is expected to reach ‪578.78 M‬ EUR.
Yes, you can track BIOMARIN PHAR. DL-,001 financials in yearly and quarterly reports right on TradingView.
Like other stocks, BM8 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOMARIN PHAR. DL-,001 stock right from TradingView charts — choose your broker and connect to your account.
BM8 reached its all-time high on Jul 20, 2015 with the price of 140.52 EUR, and its all-time low was 3.02 EUR and was reached on Nov 5, 2004.
See other stocks reaching their highest and lowest prices.
As of Apr 18, 2024, the company has ‪3.40 K‬ employees. See our rating of the largest employees — is BIOMARIN PHAR. DL-,001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOMARIN PHAR. DL-,001 EBITDA is ‪270.10 M‬ EUR, and current EBITDA margin is 12.35%. See more stats in BIOMARIN PHAR. DL-,001 financial statements.